In an 18‑year‑old male with cystic fibrosis, mild obstructive disease on prior spirometry and current cough with yellow‑green sputum, which is the most appropriate next test to assess disease severity: arterial blood gas analysis, repeat spirometry, chest radiograph, or chest computed tomography?

Spirometry Should Be Performed Next

Repeat spirometry is the most appropriate next test to assess disease severity in this patient with cystic fibrosis presenting with productive cough and respiratory symptoms. 1

Rationale for Spirometry

In CF patients experiencing respiratory symptoms suggestive of pulmonary exacerbation (productive cough with yellow-green sputum for 4 months), spirometry serves as the primary tool for assessing disease severity and documenting functional decline. The 2022 MAESTRO consensus guidelines 1 establish that pulmonary function testing (PFT), specifically spirometry, is the foundational assessment for CF lung disease monitoring and forms the basis for determining when additional imaging is warranted.

Key Clinical Context

This patient demonstrates several concerning features:

• Productive cough with purulent sputum for 4 months suggests ongoing pulmonary exacerbation
• Prior mild obstruction on spirometry 6 months ago provides a baseline for comparison
• Low BMI of 17 indicates nutritional compromise common in CF exacerbations
• History of Pseudomonas colonization increases risk for progressive lung disease

Why Spirometry Takes Priority

Spirometry directly measures functional decline, which is the clinical definition of disease severity in CF. According to the MAESTRO guidelines 1, declining lung function is defined as:

• Annual FEV₁ decrease >2% predicted in patients <12 years
• Annual FEV₁ decrease >3% predicted in patients ≥12 years (this patient is 18)

Research demonstrates that spirometry changes are highly sensitive to treatment response during exacerbations. In a study of CF patients during acute exacerbations 2, FEV₁ and FVC (percent predicted) were among the most sensitive parameters to change with treatment, alongside clinical scores.

Why Not the Other Options

Arterial blood gas (ABG) is reserved for patients with:

• Severe respiratory distress
• SpO₂ <90% on room air
• Suspected acute respiratory failure

This patient has SpO₂ 95% on room air with stable vital signs, making ABG unnecessary at this stage.

Chest radiography provides limited sensitivity for early CF lung disease changes and is generally being phased out in favor of more sensitive modalities 1, 3.

Chest CT is indicated when:

• Spirometry shows significant decline from baseline
• Clinical deterioration occurs despite treatment
• Complications are suspected (massive hemoptysis, pneumothorax, abscess)
• Baseline structural assessment is needed

The MAESTRO guidelines 1 recommend CT for pulmonary exacerbation primarily when monitoring treatment response in severe cases or when diagnosis is uncertain. Starting with spirometry allows you to quantify functional decline before exposing this young patient to ionizing radiation.

Clinical Algorithm

1. Perform spirometry immediately to compare with 6-month-old baseline
2. If FEV₁ declined ≥3% predicted: Confirms exacerbation severity, initiate aggressive treatment (antibiotics targeting Pseudomonas, airway clearance intensification)
3. If spirometry shows minimal change but symptoms persist: Consider chest CT to evaluate for structural complications (new bronchiectasis, mucus plugging, abscess)
4. Reserve ABG for acute decompensation scenarios only

Common Pitfall to Avoid

Do not skip spirometry and proceed directly to imaging based solely on symptoms. Spirometry provides objective, quantifiable data that guides treatment intensity and serves as a baseline for monitoring response. Multiple studies 2, 4 demonstrate that combining functional (spirometry) and structural (imaging when indicated) assessments provides the most comprehensive disease evaluation, but spirometry must come first in stable-to-moderate presentations.